Randomized trial: Anakinra (IL-1 receptor antagonist) does not improve outcomes in patients with mild-to-moderate COVID-19

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial – The Lancet Respiratory Medicine

Commentary: The right place for IL-1 inhibition in COVID-19 – The Lancet Respiratory Medicine

Commentary on Twitter

NEW Research—Anakinra did not improve outcomes in patients with mild-to-moderate #COVID19 pneumonia

CORIMUNO-ANA-1 trial from Xavier Mariette & colleagueshttps://t.co/SU1Cqmk9MJ pic.twitter.com/gLUkKpKinl

— The Lancet Respiratory Medicine (@LancetRespirMed) January 23, 2021